http://rdf.ncbi.nlm.nih.gov/pubchem/reference/11581215

Outgoing Links

Predicate Object
contentType Journal Article
issn 1758-8359
pageRange 17588359211068733-
publicationName Therapeutic Advances in Medical Oncology
startingPage 17588359211068733
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_a55aca0275c98e1d3d01183b153ffbc9
bibliographicCitation Wu Q, Qin Y, Liao W, Zhang M, Yang Y, Zhang P, Li Q. Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma. Ther Adv Med Oncol. 2022;14():17588359211068733. PMID: 35096146; PMCID: PMC8796084.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b12cd29c6f7b4b3764e1160b578d3386
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ab0a0218f59aac53db36f244901d2091
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_cc8272c9d1d99a5f65b7f40f242ab98c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_175c42e5ab145cae383f5f0d2f961f81
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b05bb4ce63d42c4615907b4306357e99
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2884222cd637161375cc82b8b36b956a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_645bd5c7c983695f685c121707d165d3
date 202201
identifier https://doi.org/10.1177/17588359211068733
https://pubmed.ncbi.nlm.nih.gov/35096146
https://pubmed.ncbi.nlm.nih.gov/PMC8796084
isPartOf https://portal.issn.org/resource/ISSN/1758-8359
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/37603
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7a0153350cba31da4ce6bfa8f8c68f72
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_b83d04d3e3b05ce10d1a5893dc850a9b
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7173

Total number of triples: 27.